Sun finally shines on Horizant, as FDA OK’s GSK-XenoPort RLS drug
This article was originally published in Scrip
Executive Summary
Investors jumped for joy on 7 April on the news that GlaxoSmithKline and its partner XenoPort finally gained the US FDA's blessing for their extended-release gabapentin enacarbil product Horizant (XP13512/GSK1838262) as a treatment for adults with moderate-to-severe primary restless legs syndrome (RLS) – an approval that came after a long and winding road.